(Reuters) - Zimulti, known as Acomplia in Europe, will be considered by
a U.S. Food and Drug Administration advisory panel on June 13,
and Bear Stearns analysts believe it may not get an immediate
green light.
"In view of the increasing number of scares in the industry
... we believe the FDA endocrinology division may not be keen to
make a potentially controversial decision quickly, with several
issues regarding potential side effects still outstanding," they
said in a note.
Read more at Reuters.com Government Filings News
a U.S. Food and Drug Administration advisory panel on June 13,
and Bear Stearns analysts believe it may not get an immediate
green light.
"In view of the increasing number of scares in the industry
... we believe the FDA endocrinology division may not be keen to
make a potentially controversial decision quickly, with several
issues regarding potential side effects still outstanding," they
said in a note.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment